Semnur Q3 10-Q: $54K Cash, Going Concern Doubt, $100M iHolding Deal Still Unsigned
SMNR has more than doubled off its 52-week low of $0.128.
Summary
Semnur's Q3 2026 10-Q shows $54.0 thousand of cash, a $12.6 million nine-month net loss, and a going concern warning, with the $100 million iHolding investment still only a binding term sheet at $10.00 per share and no definitive agreement signed.
Key Events · Earnings and Guidance · SMNR
-
Cash Drops to $54 Thousand
Cash and cash equivalents were $54.0 thousand at September 30, 2026, against an accumulated deficit of $288.4 million.
-
Going Concern Doubt Reaffirmed
Management concluded the conditions raise substantial doubt about the Company's ability to continue as a going concern for one year after the financial statements are issued.
-
$100M iHolding Deal Unsigned
The July 3, 2026 binding term sheet contemplates iHolding buying $100.0 million of newly issued shares at $10.00 per share, about 10,000,000 shares, but no definitive agreement had been executed as of September 30, 2026.
-
Prior Financings Terminated
The $20.0 million PIPE SPA and the $100.0 million Semnur/Biconomy Bitcoin SPA were both terminated effective April 20, 2026, leaving no committed external financing.
Analysis · SMNR · Life Sciences
Semnur closed September with just $54.0 thousand of cash against a $288.4 million accumulated deficit, and management again concluded there is substantial doubt about its ability to continue as a going concern. The only visible lifeline is the July 3, 2026 binding term sheet for iHolding to buy $100 million of newly issued stock at $10.00 per share — roughly 10,000,000 shares — but no definitive agreement had been signed as of September 30, 2026. Both prior financing backstops, the $20 million PIPE and the $100 million Biconomy Bitcoin purchase, were terminated on April 20, 2026, so the company is now dependent on Scilex funding and an unsigned term sheet. Planned spending of about $21.0 million over the next twelve months, including roughly $10.0 million of clinical work, dwarfs the cash on hand.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SMNR was trading at $0.43 on OTC in the Life Sciences sector, with a market capitalization of approximately $99M. The 52-week trading range was $0.13 to $23.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.